Gemcitabine

Generic Name: Gemcitabine

Brand Names: Gemzar

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁F_₂N_₃O_₄

CAS Number: 95058-81-4

Unique Ingredient Identifier: B76N6SBZ8R

Background: Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...

Indication: Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.

In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...

Associated Conditions: Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients

Phase 3

Completed

Conditions: Breast Cancer
Neoplasm Metastasis

Interventions: Drug: Vinorelbine
Drug: Gemcitabine

First Posted Date: 2005-08-09

Last Posted Date: 2023-05-31

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 252

Registration Number: NCT00128310

Locations: 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain
🇻🇪
Grupo Andino de Investigación en Oncología (GAICO), Valencia, Venezuela

Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary

Phase 3

Conditions: Carcinoma

First Posted Date: 2005-08-03

Last Posted Date: 2006-09-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 192

Registration Number: NCT00126269

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer

Phase 2

Completed

Conditions: Gallbladder Cancer
Biliary Tract Cancer

First Posted Date: 2005-07-26

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00123825

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Phase 2

Terminated

Conditions: Pancreatic Cancer
Neoplasm Metastasis
Adenocarcinoma

First Posted Date: 2005-06-29

Last Posted Date: 2007-06-08

Lead Sponsor: Point Therapeutics

Target Recruit Count: 60

Registration Number: NCT00116389

Locations: 🇺🇸
Gulfcoast Oncology Associates, St. Petersburg, Florida, United States
🇺🇸
Northwest Alabama Cancer Center, PC, Muscle Shoals, Alabama, United States
🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

and more 24 locations

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-06-24

Last Posted Date: 2007-10-02

Lead Sponsor: Herlev Hospital

Target Recruit Count: 60

Registration Number: NCT00115635

Locations: 🇩🇰
Dept. of Oncology, 54B1, Herlev Hospital, Herlev, Denmark

ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Paclitaxel protein-bound particles for injectable suspension (albumin-bound)

First Posted Date: 2005-05-04

Last Posted Date: 2011-06-02

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT00110084

Locations: 🇺🇸
Graham Hospital, Canton, Illinois, United States
🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸
Eureka Community Hospital, Eureka, Illinois, United States

and more 193 locations

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: cisplatin
Drug: etoposide
Drug: gemcitabine
Drug: methylprednisolone

First Posted Date: 2005-05-04

Last Posted Date: 2014-10-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 34

Registration Number: NCT00109928

Locations: 🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States
🇺🇸
Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States

and more 73 locations

Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer

Phase 1

Completed

Conditions: Neoplasms
Pancreatic Neoplasms

First Posted Date: 2005-02-02

Last Posted Date: 2009-04-30

Lead Sponsor: Threshold Pharmaceuticals

Target Recruit Count: 47

Registration Number: NCT00102752

Locations: 🇺🇸
Norton Healthcare Cancer Center, Louisville, Kentucky, United States
🇺🇸
Indiana Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States

and more 6 locations